Lipidio Pharmaceuticals focuses on advancing a molecule to treat diseases associated with excess body fat.
Lipidio Pharmaceuticals has raised $20.0M in total funding. The most recent round was Series A. The last funding was announced in November 2022.
Lipidio Pharmaceuticals's investors include 3E Bioventures, Alethea Capital Management, John Maraganore, Nancy Chang, The Foundation for Prader-Willi Research.
Lipidio Pharmaceuticals is headquartered in San Diego, United States.
Lipidio Pharmaceuticals focuses on advancing a molecule to treat diseases associated with excess body fat.
Lipidio Pharmaceuticals is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Lipidio Pharmaceuticals — Funding & Investors." VCBacked, November 10, 2022, https://www.vcbacked.co/company/lipidio-pharmaceuticals. Accessed August 14, 2026.
VCBacked. (2022). Lipidio Pharmaceuticals — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/lipidio-pharmaceuticals
{{cite web |title=Lipidio Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/lipidio-pharmaceuticals |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated